Why Is NEKTAR THERAPEUTICS (NKTR) Stock Moving Today?

Why NKTR stock is down today

Nektar Therapeutics (NKTR) shares fell 5.64% to $44.34 on Thursday, marking a sharp decline amid the release of new mid-stage trial data for its hair loss candidate, rezpegaldesleukin. The stock opened at $47.00 and hit a session high of $47.40 before falling to a low of $44.27. The drop follows mixed reactions to the clinical data and growing skepticism from investors.

What Happened

Nektar announced data from two trials of rezpegaldesleukin in alopecia and eczema, triggering immediate market response. The stock fell -21.6% in one session earlier in the week, and the new data has not reversed that trend. Analysts from H.C. Wainwright and Jefferies have commented on the selloff, with the former calling it overdone and the latter calling it unwarranted. Despite some positive assessments from William Blair, which highlighted the drug's durability edge, the broader market has remained bearish. The CEO and Chief Research and Development Officer both sold shares on August 18, signaling caution from within the company.

What The Data Shows

The stock has lost 25.6% over the last eight sessions, falling from $66.41 to $49.41. The current price of $44.34 is near the 52-week low of $33.40. Trading volume has been 1.1 million shares, slightly above the 3-month daily average. Insiders have sold $43,000 worth of shares in the last 90 days, with no insider buys recorded. The stock has printed 20 fresh 52-week lows on October 2, underscoring the bearish sentiment.

What To Watch

The company is scheduled to host a shareholder and analyst call on October 1, 2026, which may provide further insight into the drug development pipeline and management's strategy. Investors should monitor the breadth of coverage and analyst reactions in the coming days for potential shifts in sentiment.